NANOBIOTIX: insider trades · France · AMF

About NANOBIOTIX

Nanobiotix is a French late-stage clinical biotechnology company focused on developing innovative nanotherapeutic approaches, primarily for oncology. Founded in 2003 following a spin-off from research work linked to the University at Buffalo, the company is headquartered in Paris and also maintains an operational footprint in the United States, including Cambridge, Massachusetts, and New York. It has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020. The company’s business model is built around a physics-based therapeutic approach that leverages nanoparticles and nanomedicine to enhance the effectiveness of existing treatments. Its flagship program is NBTXR3, described as a first-in-class radioenhancer designed to be injected into a tumor and activated by radiotherapy in order to intensify the radiation dose delivered to cancer cells. Beyond oncology, Nanobiotix states that it owns and develops multiple nanotechnology platforms with potential applications in bioavailability and biodistribution, as well as certain central nervous system disorders. Strategically, Nanobiotix is positioned as a late-stage biotech company aiming to materially change how radiotherapy is used in cancer care, rather than offering a conventional supportive therapy. This ambition is supported by a patent estate covering several nanotechnology platforms and by key strategic partnerships. A particularly important milestone is its global licensing and co-development agreement with Janssen Pharmaceutica NV, part of Johnson & Johnson, for the commercialization pathway of its lead radioenhancer program. Historically, the company has been marked by deep scientific roots, intensive R&D investment and gradual international expansion. Its structure combines research, clinical development, manufacturing and potential commercialization capabilities, with a French base and U.S. operations supporting its global ambitions. Nanobiotix targets the worldwide oncology market, offering substantial upside potential but also the elevated execution and regulatory risk typical of clinical-stage biopharmaceutical companies. As of March 31, 2026, the company reported cash and cash equivalents of €52.8 million at December 31, 2025 and stated that its current operating plan could fund operations into early 2028, subject to certain additional funding conditions.